Uta Oelschlaegel

2.2k total citations
41 papers, 1.2k citations indexed

About

Uta Oelschlaegel is a scholar working on Hematology, Immunology and Genetics. According to data from OpenAlex, Uta Oelschlaegel has authored 41 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hematology, 11 papers in Immunology and 8 papers in Genetics. Recurrent topics in Uta Oelschlaegel's work include Acute Myeloid Leukemia Research (24 papers), Hematopoietic Stem Cell Transplantation (17 papers) and Multiple Myeloma Research and Treatments (5 papers). Uta Oelschlaegel is often cited by papers focused on Acute Myeloid Leukemia Research (24 papers), Hematopoietic Stem Cell Transplantation (17 papers) and Multiple Myeloma Research and Treatments (5 papers). Uta Oelschlaegel collaborates with scholars based in Germany, United States and France. Uta Oelschlaegel's co-authors include Gerhard Ehninger, Martin Bornhäuser, Christian Thiede, Uwe Platzbecker, Brigitte Mohr, Kay Herbrig, Jens Passauer, Frank Pistrosch, Christoph Röllig and Martin Wermke and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Uta Oelschlaegel

38 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Uta Oelschlaegel Germany 18 770 425 302 219 203 41 1.2k
Mauricio Ocqueteau Chile 13 617 0.8× 352 0.8× 214 0.7× 144 0.7× 179 0.9× 33 933
Pasquale Iacopino Italy 21 774 1.0× 255 0.6× 405 1.3× 116 0.5× 394 1.9× 72 1.3k
M. Keeney Canada 5 711 0.9× 248 0.6× 282 0.9× 58 0.3× 255 1.3× 10 1.1k
MC Cañizo Spain 16 947 1.2× 284 0.7× 157 0.5× 166 0.8× 346 1.7× 26 1.2k
A. Brizard France 17 446 0.6× 332 0.8× 125 0.4× 132 0.6× 250 1.2× 52 1.0k
R H Herzig United States 15 636 0.8× 163 0.4× 368 1.2× 200 0.9× 325 1.6× 27 1.1k
Carmelo Gurnari Italy 19 592 0.8× 364 0.9× 151 0.5× 113 0.5× 324 1.6× 141 1.0k
Mackenzie Bowman Canada 18 760 1.0× 462 1.1× 166 0.5× 31 0.1× 169 0.8× 45 1.4k
David Hakimian United States 17 295 0.4× 209 0.5× 274 0.9× 101 0.5× 657 3.2× 48 1.1k
Ozren Jakšić Croatia 15 227 0.3× 184 0.4× 233 0.8× 47 0.2× 407 2.0× 55 857

Countries citing papers authored by Uta Oelschlaegel

Since Specialization
Citations

This map shows the geographic impact of Uta Oelschlaegel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uta Oelschlaegel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uta Oelschlaegel more than expected).

Fields of papers citing papers by Uta Oelschlaegel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Uta Oelschlaegel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uta Oelschlaegel. The network helps show where Uta Oelschlaegel may publish in the future.

Co-authorship network of co-authors of Uta Oelschlaegel

This figure shows the co-authorship network connecting the top 25 collaborators of Uta Oelschlaegel. A scholar is included among the top collaborators of Uta Oelschlaegel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Uta Oelschlaegel. Uta Oelschlaegel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oelschlaegel, Uta, Susann Winter, Katja Sockel, et al.. (2024). MDS-PB13 Score - Blood based detection of aberrancies by flow cytometry in patients with suspected and confirmed Myelodysplastic Neoplasms. Leukemia. 38(2). 446–450. 1 indexed citations
2.
Stasik, Sebastian, Michael Krämer, Jan Moritz Middeke, et al.. (2022). Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML. Blood Advances. 6(11). 3294–3303. 16 indexed citations
3.
Subirá, Dolores, Canan Alhan, Uta Oelschlaegel, et al.. (2021). Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome. Annals of Hematology. 100(7). 1711–1722. 3 indexed citations
4.
Hölig, Kristina, Helmuth Schmidt, Gero Hütter, et al.. (2020). Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial. Bone Marrow Transplantation. 56(3). 635–645. 11 indexed citations
5.
Balaian, Ekaterina, Claudia Schuster, Ulrich Germing, et al.. (2016). Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q. Annals of Hematology. 95(11). 1805–1810. 10 indexed citations
6.
Schaich, Markus, Christoph Röllig, Silke Soucek, et al.. (2011). Cytarabine Dose of 36 g/m2 Compared With 12 g/m2 Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study. Journal of Clinical Oncology. 29(19). 2696–2702. 67 indexed citations
7.
Platzbecker, Uwe, Martin Wermke, J. Radke, et al.. (2011). Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 26(3). 381–389. 293 indexed citations
8.
Röllig, Christoph, Christian Thiede, Martin Gramatzki, et al.. (2010). A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood. 116(6). 971–978. 118 indexed citations
9.
Oelschlaegel, Uta, Sina Koch, Markus Schaich, et al.. (2008). A Rapid Flow Cytometric Method for the Detection of NPM1 Mutated Patients with Acute Myeloid Leukemia (AML).. Blood. 112(11). 1490–1490. 5 indexed citations
10.
Bornhäuser, Martin, Thomas Illmer, Uta Oelschlaegel, et al.. (2008). Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia. Clinical Cancer Research. 14(17). 5585–5593. 19 indexed citations
11.
Oelschlaegel, Uta, Martin Bornhäuser, Sabine Boxberger, et al.. (2007). Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma. Annals of Hematology. 86(8). 569–573. 22 indexed citations
12.
Kroschinsky, Frank, Kristina Hölig, Uwe Platzbecker, et al.. (2006). Efficacy of single‐dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion. 46(8). 1417–1423. 26 indexed citations
13.
Auffermann-Gretzinger, Susanne, Martin Bornhäuser, Knut Schäkel, et al.. (2006). Fast Appearance of Donor Dendritic Cells in Human Skin: Dynamics of Skin and Blood Dendritic Cells after Allogeneic Hematopoietic Cell Transplantation. Transplantation. 81(6). 866–873. 33 indexed citations
14.
Pistrosch, Frank, Kay Herbrig, Uta Oelschlaegel, et al.. (2005). PPARγ-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis. 183(1). 163–167. 125 indexed citations
15.
Oelschlaegel, Uta, Martin Bornhaeuser, Frank Kroschinsky, Gerhard Ehninger, & Uwe Platzbecker. (2005). Comparison of CXCR-4 and Adhesion Molecule Expression in Healthy Bone Marrow with Expression in Bone Marrow and Peripheral Blood of Patients Receiving G-CSF Plus AMD3100.. Blood. 106(11). 1974–1974. 1 indexed citations
16.
Schetelig, Johannes, Martin Bornhaeuser, Christian Thiede, et al.. (2004). Reduced-Intensity Conditioning (RIC) with Busulfan, Fludarabine and Campath-1H Is Complicated by a High Rate of Graft Failure and Severe Viral Complications in Patients with CLL.. Blood. 104(11). 5080–5080. 2 indexed citations
17.
Auffermann-Gretzinger, Susanne, Martin Bornhaeuser, Christian Thiede, et al.. (2004). Association of Skin and Blood Dendritic Cells with Acute Graft Versus Host Disease after Human Haematopoetic Cell Transplantation.. Blood. 104(11). 1238–1238. 1 indexed citations
18.
Oelschlaegel, Uta, et al.. (2003). HPC enumeration with the Sysmex XE-2100 can guide further flow cytometric CD34+ measurements and timing of leukaphereses. Cytotherapy. 5(5). 414–419. 19 indexed citations
19.
Oelschlaegel, Uta, et al.. (2001). A standardized flow cytometric method for screening paroxysmal nocturnal haemoglobinuria (PNH) measuring CD55 and CD59 expression on erythrocytes and granulocytes. Clinical & Laboratory Haematology. 23(2). 81–90. 29 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mauricio Ocqueteau Breakdown of academic impact, for papers by Pasquale Iacopino Breakdown of academic impact, for papers by M. Keeney Breakdown of academic impact, for papers by MC Cañizo Breakdown of academic impact, for papers by A. Brizard Breakdown of academic impact, for papers by R H Herzig Breakdown of academic impact, for papers by Carmelo Gurnari Breakdown of academic impact, for papers by Mackenzie Bowman Breakdown of academic impact, for papers by David Hakimian Breakdown of academic impact, for papers by Ozren Jakšić
Rankless by CCL
2026